GlassScriptPhysician profile
Suleiman Kojan
NPI 1629503024
$4,114.66
in general payments reported to CMS, 2019-2025
24 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what 75% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $110 · 2023: $966 · 2024: $1,369 · 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,516 · Education: $156 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,516.35 |
| Education | $156.00 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,072.49 | 2022-2025 | Briviact, Fintepla, Nayzilam |
| Abbvie INC. | $387.65 | 2023-2025 | |
| Emd Serono, INC. | $374.45 | 2023-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $360.85 | 2021-2025 | |
| Biogen, INC. | $227.91 | 2023-2025 | Tysabri, Skyclarys, Vumerity |
| Eisai INC. | $220.43 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $190.15 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $164.88 | 2024-2025 | Hyqvia |
| Amgen INC. | $127.93 | 2023-2025 | Uplizna, Aimovig |
| Neurelis, INC. | $119.73 | 2023-2025 | Valtoco |
| Genzyme Corporation | $87.70 | 2023-2025 | |
| Pfizer INC. | $86.16 | 2024-2025 | |
| Celgene Corporation | $84.73 | 2023-2025 | Zeposia |
| Kyowa Kirin, INC. | $78.30 | 2023-2024 | Nourianz |
| Teva Pharmaceuticals USA, INC. | $76.50 | 2023-2025 | Austedo Xr, Ajovy, Austedo Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $73.52 | 2023-2025 | |
| Horizon Therapeutics Plc | $73.11 | 2023 | Uplizna |
| Catalyst Pharmaceuticals, INC. | $58.60 | 2024 | |
| Lilly USA, LLC | $51.58 | 2023-2024 | Emgality, Reyvow |
| Genentech USA, INC. | $47.89 | 2023-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Lundbeck LLC | $46.45 | 2023-2025 | Rexulti |
| Tanabe Pharma America, INC. | $45.85 | 2024 | |
| Neurocrine Biosciences, INC. | $34.20 | 2023-2025 | Ingrezza, Ongentys |
| Janssen Pharmaceuticals, INC | $23.60 | 2023 | Ponvory |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suleiman Kojan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.